论文部分内容阅读
替罗非班属于血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂,是目前国内临床所应用的最强的抗血小板聚集的药物,能有效改善心肌灌注;我院在对急性前壁心肌梗死行急诊冠状动脉介入治疗(PCI)的同时联合早期应用替罗非班治疗,以增强心肌微循环再灌注。本文就我院对急性前壁心肌梗死患者采用急诊PCI同时联合早期应用替罗非班治疗的临床疗效总结如下。
Tirofiban is a platelet glycoprotein Ⅱ b / Ⅲ a receptor antagonist, is currently the clinical application of the strongest anti-platelet aggregation drugs, can effectively improve myocardial perfusion; my hospital in the acute anterior myocardial infarction emergency coronal Arterial intervention (PCI) combined with early use of tirofiban in combination to enhance myocardial reperfusion after microcirculation. This article on our hospital acute acute myocardial infarction patients with emergency PCI combined with early application of tirofiban treatment of clinical efficacy are summarized below.